Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

The efficacy of α1 proteinase inhibitor (A1PI) augmentation treatment for α1 antitrypsin deficiency has not been substantiated by a randomised, placebo-controlled trial. CT-measured lung density is a more sensitive measure of disease progression in α1 antitrypsin deficiency emphysema than spirometry is, so we aimed to assess the efficacy of augmentation treatment with this measure.

Detaljer

Författare
  • Kenneth R Chapman
  • Jonathan G W Burdon
  • Eeva Piitulainen
  • Robert A Sandhaus
  • Niels Seersholm
  • James M Stocks
  • Berend C Stoel
  • Liping Huang
  • Zhenling Yao
  • Jonathan M Edelman
  • Noel G McElvaney
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Lungmedicin och allergi
Originalspråkengelska
Sidor (från-till)360-368
TidskriftThe Lancet
Volym386
Utgåva nummer9991
StatusPublished - 2015
PublikationskategoriForskning
Peer review utfördJa